# Tesamorelin Half-Life and Pharmacokinetics in the Research Literature > Tesamorelin half-life: apparent plasma clearance ~1,060 L/h and a terminal half-life around 26-45 minutes in preclinical work, yet IGF-1 persists across the dosing interval. Cited. The PK paradox in two cells: a parent peptide that clears in minutes beside an IGF-1 effect that holds across a full once-daily interval. ## The short version Here is the tesamorelin half-life story in plain terms. Once injected, the drug itself disappears from the blood fast — within roughly half an hour to three-quarters of an hour in animal studies [8][9]. But the effect it sets off lasts much longer: it tells the body to release growth hormone, which raises IGF-1 (a growth signal the liver makes), and that IGF-1 stays elevated all day [6]. So the drug clears quickly, but its job keeps getting done. That mismatch — fast clearance, slow-fading effect — is why the studied schedule was once a day. ## Apparent plasma clearance Tesamorelin clears rapidly from plasma. A population pharmacokinetic analysis in HIV patients and healthy subjects (1-2 mg/day subcutaneously for 14 days) estimated apparent plasma clearance (CL/F) at approximately 1,060 L/h [6]. That is a high clearance, consistent with a peptide that does not linger. The same analysis found the absorbed fraction was about 13% higher on day 14 than day 1, and identified no clinically relevant demographic covariates — age, weight, sex, and HIV status did not meaningfully alter the pharmacokinetics [6]. ## What is the half-life of tesamorelin? Plasma exposure is short. Preclinical studies measured a terminal elimination half-life of roughly 21 to 45 minutes in dogs after intravenous or subcutaneous dosing up to 600 microg/kg [8], and approximately 26 minutes after subcutaneous dosing in a separate canine pharmacokinetic study [9]. Secondary clinical sources describe a terminal half-life on the order of 26-38 minutes [14]. Population modeling characterized the human clearance as rapid (CL/F ~1,060 L/h) [6]. Across these sources the message is consistent: the parent peptide does not persist in plasma. ## How Long Does Tesamorelin Stay in the System? The parent peptide clears from plasma within an hour or so, given its rapid apparent clearance (~1,060 L/h) [6] and a terminal half-life measured at roughly 26-45 minutes in preclinical work [8][9]. But its pharmacodynamic effect outlasts the measurable drug: by stimulating growth hormone, tesamorelin raises IGF-1, and that elevation persists across the dosing interval [6]. The drug leaves the system quickly; the downstream signal it triggers does not. This is precisely why the regimen studied in trials was once daily rather than multiple times a day. ## Clearance versus IGF-1 persistence: the PK paradox The defining feature of tesamorelin pharmacokinetics is the gap between drug exposure and drug effect. The parent peptide is cleared in minutes [6][8], yet a population pharmacokinetic-pharmacodynamic model confirmed it stimulates growth hormone in an episodic (pulsatile) manner, and the resulting IGF-1 elevation is sustained across a full once-daily interval [7]. Mechanistically this makes sense: tesamorelin's job is to fire the pituitary's growth-hormone release, and once growth hormone rises, the liver's IGF-1 response unfolds on a slower clock than the peptide's own clearance. Short half-life, long shadow. The DPP-IV resistance conferred by the trans-3-hexenoic acid N-terminal group is what lets the molecule act at all before it clears — native GHRH is degraded even faster [8]. ## Preclinical exposure and the DPP-IV-resistance signature The preclinical record is where the half-life was first pinned down. Adding the trans-3-hexenoyl moiety to Tyr1 of human GRF(1-44)NH2 rendered the analogue resistant to dipeptidyl aminopeptidase-IV deactivation, slowing its in vitro degradation in rat, dog, and human plasma and prolonging in vivo elimination — with an apparent elimination half-life of 21 to 45 minutes in dogs after intravenous or subcutaneous dosing up to 600 microg/kg, plus dose-related exposure and dose-related rises in growth hormone and IGF-1 [8]. The route comparison is instructive. In beagle dogs, intratracheal dry-powder delivery gave a bioavailability of 41% relative to subcutaneous injection (13% absolute), with a comparable terminal half-life (intratracheal ~39 minutes vs subcutaneous ~26 minutes) and a longer mean residence time after inhalation (74 vs 52 minutes) [9]. Whatever the route, the parent peptide is short-lived — the half-life sits in the tens-of-minutes range, and the durability of effect comes from the downstream GH/IGF-1 response, not from the peptide lingering. ## Drug-interaction pharmacokinetics Tesamorelin showed minimal effect on drug-metabolizing enzymes. In two randomized two-way crossover studies in healthy volunteers, 2 mg tesamorelin on Days 1-7 had minimal impact on CYP3A activity (the major drug-metabolizing enzyme system): the exposure (AUC) ratios for co-administered simvastatin and ritonavir on Day 6 stayed within the 80-125% no-effect range, with only a minor reduction in ritonavir peak concentration, indicating co-administration without dose adjustment [10]. For a peptide cleared so rapidly, a clean interaction profile is unsurprising — there is little parent drug present to perturb hepatic enzyme activity. ## Does tesamorelin need to be refrigerated? The approved product is supplied as a lyophilized powder requiring reconstitution, and published handling notes specify refrigerated storage and use of the reconstituted solution within a defined window [14]. The molecule's plasma stability comes from the DPP-IV-blocking N-terminal modification [8], but that is a metabolic property, not a shelf-stability one. Research-grade material handling follows laboratory protocols rather than a self-administration regimen; this is reported as a handling note, not an instruction. --- tesamorelin catalogued cell by cell on a nine-panel reference board — every visceral-fat figure, the minutes-fast plasma clearance against the day-long IGF-1 effect, and the FDA-approved-only-for-HIV-lipodystrophy boundary filed to its study; a laboratory reference grid, not a clinic, a vendor, or a prescription.